Factors determining response to Hydroxychloroquine therapy in palindromic rheumatism
Jayaprakash, A.; K, S.
Journal of the Association of Physicians of India 68(1): 69
2020
ISSN/ISBN: 0004-5772 PMID: 31979694 Document Number: 18051
Document emailed within 1 workday
Related Documents
Schwartzberg, M. 1982: Prophylactic colchicine therapy in palindromic rheumatism Journal of Rheumatology 9(2): 341-343Finn, B.C.; Young, P.; Laborde, H.; Earsman, G.; Noe, Dán.Duartes.; Barreira, J.C.; Bruetman, J.E. 2010: Palindromic rheumatism. Report of one case Revista Medica de Chile 138(7): 852-855
Genth-Stolzenburg, S. 1996: Rheumatism: a too long pathway to adequate therapy. Experiences of a physician as rheumatism patient Fortschritte der Medizin 114(1-2): 19
Veraldi, S.; Schianchi-Veraldi, R.; Scarabelli, G. 1992: Pigmentation of the gums following hydroxychloroquine therapy Cutis 49(4): 281-282
Byśkiniewicz, K. 2006: Factors determining the decision to initiate nCPAP therapy in patients with obstructive sleep apnea (OSA) Pneumonologia i Alergologia Polska 74(1): 45-50
Radivoievici, A.; Tomescu, N.; Zorleanu, N.; Schauer, C.; Socolov, M. 1972: Genetic factors as risk factors in acute polyarticular rheumatism Medicina Interna 24(4): 489-496
Bloom, B.J.; Tucker, L.B.; Klein-Gitelman, M.; Miller, L.C.; Schaller, J.G. 1994: Worsening of the rash of juvenile dermatomyositis with hydroxychloroquine therapy Journal of Rheumatology 21(11): 2171-2172
Biasi, D.; Caramaschi, P.; Carletto, A.; Pacor, M.L.; Bambara, L.M. 1997: Safety of combination therapy with hydroxychloroquine, gold sodium thiomalate and methotrexate in early rheumatoid arthritis Revue du Rhumatisme 64(7-9): 521-522
2003: Tolerable pain therapy in rheumatism saves long-term costs. Despite this most COX-2 candidates receive conventional NSAID therapy MMWFortschrittederMedizin 145(29-30): 61
Kaiser, H. 1998: Glucocorticoids in the therapy of rheumatism. 2: Systemic corticoid therapy Fortschritte der Medizin 116(34): 41-43
Briko, N.I.; Shmidt, E.I.; Grushchinskaia, I.A.; Shikhman, A.R. 1989: The secretory and systemic humoral immune response to polysaccharide a in patients with rheumatism Vestnik Akademii Meditsinskikh Nauk SSSR 6: 37-38
Briko, N.I.; Shmidt, E.I.; Grushchinskaia, I.A.; Shikhman, A.R. 1989: The secretory and systemic humoral immune response to polysaccharide A in patients with rheumatism Vestnik Akademii Meditsinskikh Nauk SSSR 6: 37-38
Singer, E. 1976: Sociopsychological factors influencing response to levodopa therapy for Parkinson's disease Archives of Physical Medicine and Rehabilitation 57(1): 328-334
Segond, P.; Delfraissy, J.F.; Galanaud, P.; Dormont, J.; Massias, P. 1979: In vitro study of the primary antibody response of circulating lymphocytes in patients with chronic inflammatory rheumatism Revue du Rhumatisme et des Maladies Osteo-Articulaires 46(12): 697-704
Amanzholova, S.A. 1996: Antistreptococcal immunity in rheumatism and urban ecological risk factors Terapevticheskii Arkhiv 68(5): 45-47
Heinzl, S. 1999: Progress in the therapy of rheumatism Medizinische Monatsschrift für Pharmazeuten 22(8): 225
Anokhin, V.N.; Novikova, I.I.; Stulova, M.A. 1980: Debatable questions of rheumatism therapy Klinicheskaia Meditsina 58(4): 50-55
Tseng, T-Chung.; Liu, C-Jen.; Wang, C-Chi.; Chen, P-Jer.; Lai, M-Yang.; Chen, D-Shinn.; Kao, J-Horng. 2009: Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels Antiviral Therapy 14(2): 203-210
Khrustalev, O.A. 1995: The effect of clinical and hemodynamic factors on the dynamic development over the course of 1 year of observation of heart failure in rheumatism patients Terapevticheskii Arkhiv 67(8): 37-39
Syed, N.Naz.; Adil, S.Naseem.; Sajid, R.; Usman, M.; Moiz, B.; Kakepoto, G.Nabi.; Khurshid, M. 2007: Chronic ITP: analysis of various factors at presentation which predict failure to first line treatment and their response to second line therapy Jpma. Journal of the Pakistan Medical Association 57(3): 126-129